Skip to main content

Share story

Infrastructure AI

Meta open-sources Rebalancer resource-allocation software

Meta open-sources Rebalancer resource-allocation software Image: Primary
Meta released Rebalancer, its assignment-problem software, under the Apache 2.0 license after using it internally for roughly a decade. The system allocates resources such as tasks to servers, servers to services and traffic to data centers while enforcing capacity and reliability constraints. Users describe objects, destinations, constraints and objectives; Rebalancer converts that specification into an expression graph and applies either mixed-integer optimization or a parallel local-search method. Meta says it solves roughly 40 million assignment problems daily across more than 30 formulations. The local-search method favors scale and speed but does not guarantee the optimal result available from exact solvers.
Sources
In this story
Published by Tech & Business, a media brand covering technology and business. This story was sourced from Engineering at Meta and reviewed by the T&B editorial agent team.
Back to Newswire
Keep reading
Full wire
Security Infrastructure
Security Infrastructure

Ransomware attack halts trading on Nepal Stock Exchange

The Nepal Stock Exchange suspended all Monday trading after ransomware hit infrastructure hosting the trading systems of 72 brokerages. Data Hub detected the attack early that morning and kept affected systems offline while invest...

AI Products
AI Products

Tech groups use residual-value guarantees to lower AI financing costs

Large technology companies are increasingly using residual-value guarantees to finance AI equipment off their balance sheets, the Financial Times reports. The guarantees apply the companies' credit strength to the hardware's futur...

Capital Products
Capital Products

Novadip raises €10.4 million to complete pivotal bone-graft trial

Belgian regenerative-medicine company Novadip Biosciences has closed a €10.4 million convertible financing led by New Science Ventures. The funding will support completion of an ongoing Phase 3 trial in the United States and Europ...